With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Peak Pruritus NRS (PP-NRS)
Timeframe: From enrollment to 52 weeks of treatment
Investigator Global Assessment scale of Prurigo Nodularis stage (IGA-PN)
Timeframe: From enrollment to 52 weeks of treatment
Drug survival
Timeframe: From enrollment to 52 weeks of treatment
Adverse events
Timeframe: From enrollment to 52 weeks of treatment
Skin homing T cell subtypes
Timeframe: Up to 52 weeks of treatment
Serum levels of relevant proteins
Timeframe: Up to 52 weeks of treatment
Systemic epigenetic changes
Timeframe: Up to 52 weeks of treatment